Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
10.3779/j.issn.1009-3419.2015.10.10
- VernacularTitle:肺腺癌靶向治疗后小细胞肺癌转化的病例报道
- Author:
XUE SHUPING
1
;
YU TINGTING
;
ZHANG YAN
;
SHAN LI
Author Information
1. 新疆医科大学附属肿瘤医院肺内一科
- Keywords:
Lung neoplsms;
EGFR mutation;
Resistance
- From:
Chinese Journal of Lung Cancer
2015;(10):656-660
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS);With the great devel-opment of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. hTis paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs. Atfer disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. hTrough the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.
